63 results
8-K
EX-10.1
RGLS
Regulus Therapeutics Inc
14 Mar 24
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
4:57pm
file or pay would not result in a Material Adverse Effect on the Company. There is no material proposed tax deficiency, assessment, charge or levy … be disclosed in the SEC Documents that has not been so disclosed, except for any such deficiency, assessment, charge or levy which, individually
8-K
EX-99.1
ahdh7oktdaatm
13 Apr 23
Securities Purchase Agreement
4:05pm
8-K
EX-99.1
3ulrn 88u5y
30 Nov 21
Securities Purchase Agreement
5:27pm